citalopram has been researched along with Dysthymia in 11 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Numerous studies have assessed the acute efficacy of antidepressants, including selective serotonin reuptake inhibitors, in treating dysthymic disorder; however, escitalopram, the S-enantiomer of citalopram, has not been studied." | 9.14 | Escitalopram versus placebo in the treatment of dysthymic disorder. ( Arnaout, B; Batchelder, ST; Benga, I; Gangure, D; Hellerstein, DJ; Hyler, S; Toba, C, 2010) |
| "This study aimed to provide preliminary data on the tolerability and effectiveness of citalopram for patients with dysthymic disorder." | 9.11 | Citalopram in the treatment of dysthymic disorder. ( Batchelder, S; Clark, J; Gangure, D; Hellerstein, DJ; Hyler, S; Kreditor, D; Miozzo, R, 2004) |
| "We studied 15 patients with dysthymic disorder with open-label citalopram." | 9.10 | Dysthymic disorder: treatment with citalopram. ( Bea, C; Budech, CB; Dunner, DL; Friedman, SD; Hendricksen, HE, 2002) |
| "Relatively treatment-naive depressed outpatients (with DSM-IV diagnoses of major depressive disorder, dysthymic disorder, or depression not otherwise specified) were initially treated with a combination of escitalopram (ESC) plus bupropion (BUP), using rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15 in an open-label, 8-week study." | 5.14 | Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? ( Deliyannides, RA; McGrath, PJ; Quitkin, FM; Stewart, JW, 2009) |
| "Numerous studies have assessed the acute efficacy of antidepressants, including selective serotonin reuptake inhibitors, in treating dysthymic disorder; however, escitalopram, the S-enantiomer of citalopram, has not been studied." | 5.14 | Escitalopram versus placebo in the treatment of dysthymic disorder. ( Arnaout, B; Batchelder, ST; Benga, I; Gangure, D; Hellerstein, DJ; Hyler, S; Toba, C, 2010) |
| "This study aimed to provide preliminary data on the tolerability and effectiveness of citalopram for patients with dysthymic disorder." | 5.11 | Citalopram in the treatment of dysthymic disorder. ( Batchelder, S; Clark, J; Gangure, D; Hellerstein, DJ; Hyler, S; Kreditor, D; Miozzo, R, 2004) |
| "We studied 15 patients with dysthymic disorder with open-label citalopram." | 5.10 | Dysthymic disorder: treatment with citalopram. ( Bea, C; Budech, CB; Dunner, DL; Friedman, SD; Hendricksen, HE, 2002) |
| "The treatment of dysthymia in itself poses a problem in the everyday psychiatric practice and it can be further hindered when accompanied by pronounced personality traits (which are indicative of disorder)." | 1.37 | Allergic reactions--outcome of sertraline and escitalopram treatments. ( Dadić-Hero, E; Grahovac, T; Graovac, M; Palijan, TZ; Ružić, K; Sepić-Grahovac, D, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vidyasagar, S | 1 |
| Rao, K | 1 |
| Verma, M | 1 |
| Tripuraneni, AD | 1 |
| Patil, N | 1 |
| Bhattacharjee, D | 1 |
| Ho, PS | 1 |
| Yeh, YW | 1 |
| Huang, SY | 1 |
| Liang, CS | 1 |
| Amitai, M | 1 |
| Kronenberg, S | 1 |
| Carmel, M | 1 |
| Michaelovsky, E | 1 |
| Frisch, A | 1 |
| Brent, D | 1 |
| Apter, A | 1 |
| Chen, A | 1 |
| Weizman, A | 1 |
| Fennig, S | 1 |
| Lehto, SM | 1 |
| Tolmunen, T | 1 |
| Kuikka, J | 1 |
| Valkonen-Korhonen, M | 1 |
| Joensuu, M | 1 |
| Saarinen, PI | 1 |
| Vanninen, R | 1 |
| Ahola, P | 1 |
| Tiihonen, J | 1 |
| Lehtonen, J | 1 |
| Stewart, JW | 1 |
| McGrath, PJ | 1 |
| Deliyannides, RA | 1 |
| Quitkin, FM | 1 |
| Dadić-Hero, E | 1 |
| Ružić, K | 1 |
| Grahovac, T | 1 |
| Graovac, M | 1 |
| Palijan, TZ | 1 |
| Sepić-Grahovac, D | 1 |
| Hellerstein, DJ | 2 |
| Batchelder, ST | 1 |
| Hyler, S | 2 |
| Arnaout, B | 1 |
| Toba, C | 1 |
| Benga, I | 1 |
| Gangure, D | 2 |
| Batchelder, S | 1 |
| Miozzo, R | 1 |
| Kreditor, D | 1 |
| Clark, J | 1 |
| Bastiaens, L | 1 |
| Rosenberg, C | 1 |
| Lauritzen, L | 1 |
| Brix, J | 1 |
| Jørgensen, JB | 1 |
| Kofod, P | 1 |
| Bayer, LB | 1 |
| Dunner, DL | 1 |
| Hendricksen, HE | 1 |
| Bea, C | 1 |
| Budech, CB | 1 |
| Friedman, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication.[NCT00296712] | Phase 4 | 55 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder[NCT00220701] | Phase 4 | 36 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression. (NCT00220701)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 15.00 |
| Placebo | 16.25 |
21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression. (NCT00220701)
Timeframe: Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 6.76 |
| Placebo | 10.00 |
Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology) (NCT00220701)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 4.06 |
| Placebo | 4.06 |
Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology) (NCT00220701)
Timeframe: Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 2.35 |
| Placebo | 3.41 |
Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (>50% decrease) Remission (score<=7) (NCT00220701)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 22.82 |
| Placebo | 24.41 |
Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (>50% decrease) Remission (score<=7) (NCT00220701)
Timeframe: Week 12
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram | 10.88 |
| Placebo | 16.41 |
6 trials available for citalopram and Dysthymia
| Article | Year |
|---|---|
Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Child; Citalopram; Depressive Disorder, Major; Dysthymic Disorder; Fe | 2016 |
Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Depress | 2009 |
Escitalopram versus placebo in the treatment of dysthymic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Dose-Response Relationship, Drug; Doubl | 2010 |
Citalopram in the treatment of dysthymic disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cognition; Dose-Response Relationship, | 2004 |
Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice.
Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Age | 2007 |
Dysthymic disorder: treatment with citalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Double-Blind Method; Dysthymic Disorder | 2002 |
5 other studies available for citalopram and Dysthymia
| Article | Year |
|---|---|
Escitalopram Induced SIADH in an Elderly Female: A Case Study.
Topics: Citalopram; Dysthymic Disorder; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Middle Age | 2017 |
A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram.
Topics: Adult; Antidepressive Agents; Case-Control Studies; Citalopram; Cytokines; Depressive Disorder; Depr | 2015 |
Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study.
Topics: Adult; Binding, Competitive; Biomarkers; Citalopram; Corpus Striatum; Depressive Disorder, Major; Di | 2008 |
Allergic reactions--outcome of sertraline and escitalopram treatments.
Topics: Adult; Angioedema; Antidepressive Agents; Citalopram; Combined Modality Therapy; Drug Eruptions; Dru | 2011 |
Adolescents' response to antidepressant treatment in a community mental health center.
Topics: Adolescent; Adolescent Psychiatry; Algorithms; Antidepressive Agents; Child; Child Psychiatry; Cital | 2005 |